Non-steroidal anti-inflammatory drugs

Last updated: November 01, 2022

Non-steroidal anti-inflammatory drugs

Block 3 CVH

Block 3 CVH

Angina pectoris
Stable angina
Ludwig angina
Unstable angina
Prinzmetal angina
Heart failure
Heart failure: Pathology review
Stroke volume, ejection fraction, and cardiac output
Congestive heart failure: Clinical sciences
Dilated cardiomyopathy
Restrictive cardiomyopathy
Frank-Starling relationship
Myocardial infarction
Acute coronary syndrome: Clinical sciences
ECG cardiac infarction and ischemia
Loop diuretics
Thiazide and thiazide-like diuretics
Potassium sparing diuretics
cGMP mediated smooth muscle vasodilators
ACE inhibitors, ARBs and direct renin inhibitors
Positive inotropic medications
Coronary artery disease: Clinical sciences
Adrenergic antagonists: Beta blockers
Calcium channel blockers
Coronary artery disease: Pathology review
Hereditary spherocytosis
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Approach to anemia (destruction and sequestration): Clinical sciences
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Pyruvate kinase deficiency
Paroxysmal nocturnal hemoglobinuria
Warm autoimmune hemolytic anemia and cold agglutinin (NORD)
Lead poisoning
Oxygen-hemoglobin dissociation curve
Sickle cell disease (NORD)
Sickle cell disease: Clinical sciences
Beta-thalassemia
Beta-thalassemia: Year of the Zebra
Alpha-thalassemia
Mitral valve disease
Valvular heart disease: Pathology review
Valvular insufficiency (regurgitation): Clinical sciences
Abnormal heart sounds
Aortic stenosis: Clinical sciences
Aortic valve disease
Infectious endocarditis: Clinical sciences
Acute rheumatic fever and rheumatic heart disease: Clinical sciences
Rheumatic heart disease
Tricuspid valve disease
Pulmonary valve disease
Persistent truncus arteriosus
Transposition of the great vessels
Approach to congenital heart diseases (cyanotic): Clinical sciences
Tetralogy of Fallot
Tetralogy of Fallot: Year of the Zebra
Total anomalous pulmonary venous return
Ventricular septal defect
Approach to congenital heart diseases (acyanotic): Clinical sciences
Atrial septal defect
Patent ductus arteriosus
Acyanotic congenital heart defects: Pathology review
Coarctation of the aorta
Cardiac tumors
Cardiac and vascular tumors: Pathology review
Carcinoid syndrome
Hypertension: Pathology review
Hypertension
Hypertensive emergency
Pulmonary hypertension
Essential hypertension: Clinical sciences
Pulmonary hypertension: Clinical sciences
Approach to hypertension: Clinical sciences
Cor pulmonale
Pulmonary arterial hypertension (NORD)
Cardiomyopathies: Pathology review
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy: Clinical sciences
Cardiac conduction velocity
Cardiac conduction system
ECG cardiac hypertrophy and enlargement
ECG axis
ECG intervals
ECG basics
ECG QRS transition
ECG rate and rhythm
ECG normal sinus rhythm
Atrial fibrillation
Supraventricular arrhythmias: Pathology review
Atrial flutter
Ventricular fibrillation
Ventricular arrhythmias: Pathology review
Atrioventricular block: Clinical sciences
Atrioventricular block
Heart blocks: Pathology review
Long QT syndrome and Torsade de pointes
Brugada syndrome
Pericarditis and pericardial effusion
Pericarditis: Clinical sciences
Recurrent pericarditis (NORD)
Pericardial disease: Pathology review
Cardiac tamponade: Clinical sciences
Myocarditis
Shock
Approach to shock: Clinical sciences
Shock: Pathology review
Iron deficiency and iron deficiency anemia (pediatrics): Clinical sciences
Iron deficiency anemia
Iron deficiency anemia: Clinical sciences
Anemia of chronic disease: Year of the Zebra
Anemia of chronic disease
Folate (Vitamin B9) deficiency
Anemia in pregnancy: Clinical sciences
Vitamin B12 deficiency
Vitamin B12 deficiency: Clinical sciences
Orotic aciduria
Diamond-Blackfan anemia
Sideroblastic anemia
Approach to anemia in the newborn and infant (underproduction): Clinical sciences
Acute intermittent porphyria
Porphyria cutanea tarda
Aplastic anemia
Non-hemolytic normocytic anemia: Pathology review
Fanconi anemia
Megaloblastic anemia
Macrocytic anemia: Pathology review
Autoimmune hemolytic anemia
Microcytic anemia: Pathology review
Pernicious anemia: Year of the Zebra
Approach to anemia in the newborn and infant (destruction and blood loss): Clinical sciences
Approach to anemia (underproduction): Clinical sciences
Epstein-Barr virus (Infectious mononucleosis)
Bartonella henselae (Cat-scratch disease and Bacillary angiomatosis)
Acute leukemia
Approach to leukemia: Clinical sciences
Leukemias: Pathology review
Approach to myeloproliferative neoplasms: Clinical sciences
Chronic leukemia
Myeloproliferative disorders: Pathology review
Non-Hodgkin lymphoma
Lymphomas: Pathology review
Approach to lymphoma: Clinical sciences
Hodgkin lymphoma
Multiple myeloma: Clinical sciences
Multiple myeloma
Waldenstrom macroglobulinemia
Plasma cell disorders: Pathology review
Amyloidosis
Monoclonal gammopathy of undetermined significance
Myelodysplastic syndromes
Approach to myelodysplastic syndromes: Clinical sciences
Polycythemia vera (NORD)
Essential thrombocythemia (NORD)
Myelofibrosis (NORD)
Mastocytosis (NORD)
Langerhans cell histiocytosis
Langerhans cell histiocytosis: Year of the Zebra
Non-steroidal anti-inflammatory drugs
Antiplatelet medications
Anticoagulants: Direct factor inhibitors
Thrombolytics
Anticoagulants: Heparin
Heparin-induced thrombocytopenia
Anticoagulants: Warfarin
Osmotic diuretics
Sympatholytics: Alpha-2 agonists
Sympathomimetics: Direct agonists
Wiskott-Aldrich syndrome
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Premature ventricular contraction
Supraventricular tachycardia: Clinical sciences
Wolff-Parkinson-White syndrome
Anatomy clinical correlates: Heart
Approach to bradycardia: Clinical sciences
Premature atrial contraction
Bundle branch block
Approach to a murmur (pediatrics): Clinical sciences
Approach to cyanosis (newborn): Clinical sciences
Cyanotic congenital heart defects: Pathology review
Williams syndrome
Hypoplastic left heart syndrome
Hypoplastic left heart syndrome: Year of the Zebra 2024
Kawasaki disease
Kawasaki disease: Clinical sciences
Approach to chest pain: Clinical sciences
Ventricular tachycardia: Clinical sciences
Approach to syncope: Clinical sciences
Approach to tachycardia: Clinical sciences
Atrioventricular nodal reentrant tachycardia (AVNRT)
Approach to acid-base disorders: Clinical sciences
Acid-base map and compensatory mechanisms
The role of the kidney in acid-base balance
Acid-base disturbances: Pathology review
Plasma anion gap
Approach to metabolic acidosis: Clinical sciences
Metabolic acidosis
Metabolic alkalosis
Respiratory alkalosis
Approach to metabolic alkalosis: Clinical sciences
Approach to respiratory alkalosis: Clinical sciences
Renal tubular acidosis
Respiratory acidosis
Approach to respiratory acidosis: Clinical sciences
Neuroblastoma
Neuroblastoma: Year of the Zebra 2024
Nephroblastoma (Wilms tumor)

Transcript

Watch video only

Non-steroidal anti-inflammatory drugs or NSAIDs are mainly used to treat inflammation, pain, and fever. These conditions are related to an increased production of pro-inflammatory chemicals called prostaglandins.

NSAIDs work by decreasing the production of prostaglandins, thereby reducing inflammation, relieving pain, and reducing fever.

In order to understand how NSAIDs work, first we need to talk briefly about inflammation, which is the body’s response to a harmful stimulus, such as infection or injury.

So, during inflammation, your immune cells use an enzyme called phospholipase A2 to take membrane phospholipids and make a 20-carbon polyunsaturated fatty acid, called arachidonic acid.

Arachidonic acid is a substrate for an enzyme called cyclooxygenase or COX.

The enzyme cyclooxygenase exists in two different isoforms: COX-1 and COX-2.

COX-1 is a constitutive enzyme, meaning that it’s always active, while on the other hand, COX-2 is an inducible enzyme, meaning that it must be turned on to function. This is usually triggered by immune cells and vascular endothelial cells during inflammation.

Both enzymes produce prostaglandin E2 (PGE2) and prostacyclin (PGI2), which cause vasodilation and attract different immune cells to the area.

They also act on neurons that detect pain, called nociceptors, and make them more sensitive to stimuli by lowering their threshold for activation.

Finally, they stimulate the hypothalamus to increase the body temperature, causing fever.

Prostaglandin E2 also has other effects like causing uterine contractions, decreasing the secretion of acid, and increasing the production of protective mucus in the stomach.

So, in conditions such as inflammation, pain, or fever, NSAIDs can be used to inhibit cyclooxygenase and decrease the production of prostaglandins.

Depending on how they interact with these enzymes, NSAIDs are subdivided into 2 main groups: irreversible COX inhibitors, like aspirin; and reversible COX inhibitors, or non-aspirin NSAIDs.

Non-aspirin NSAIDs can be further subdivided into 2 groups: non-selective COX inhibitors, which include common medications like ibuprofen, and selective COX-2 inhibitors like celecoxib.

Alright, now let’s start with aspirin, also known as acetylsalicylic acid, which works by irreversibly inhibiting both COX-1 and COX-2.

Aspirin is taken perorally and most of the absorption occurs in the ileum.

Once absorbed into the bloodstream, aspirin irreversibly inhibits COX-1 in platelets by covalent acetylation, thereby decreasing production of thromboxane A2 in platelets.

Since thromboxane A2 is a platelet activator, this makes aspirin useful as an antiplatelet medication.

Since aspirin irreversibly prevents the platelets from synthesizing new COX-1 enzymes, aspirin’s effect will persist until there are enough new platelets produced that are able to produce COX-1 enzymes. This leads to increased bleeding time without affecting PT or PTT.

Next, in the liver, aspirin is metabolized into salicylate, which doesn’t have the antiplatelet effect, but it does have anti-inflammatory properties.

Salicylate works by inhibiting COX-2, thereby reducing prostaglandin production, leading to decreased inflammation, pain, and fever; so, it’s commonly used to treat headaches and musculoskeletal pain.

It’s also used for the short term treatment of chronic pain like osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

It’s important to note that the effects of aspirin are dose-dependent: low doses under 300 mg/day work as an antiplatelet medication; medium doses between 300 and 2400 mg/day work as an antipyretic and analgesic; and high doses over 2400 mg/day work as an anti-inflammatory medication.

Low doses or “baby aspirin” in the form of 81 mg tablets are used long-term to help prevent heart attacks, strokes, and blood clot formation in people at high risk of developing blood clots.

Okay, moving on to non-selective COX inhibitors, which reversibly inhibit both COX-1 and COX-2. Common medications in this class include ibuprofen, naproxen, ketorolac, indomethacin, sulindac, meloxicam, and many others.

All these medications can be taken perorally, but ketorolac, ibuprofen, and indomethacin are the only NSAIDs that are also available in parenteral form.

Just like aspirin, these medications also inhibit COX-1 and have an antiplatelet effect, but because they’re reversible inhibitors, their effect is transient so they won’t provide the same benefit as aspirin.

If taken together with aspirin, they will even compete for the binding sites on COX-1, which results in a decrease in the antiplatelet effect of aspirin.

Next, these medications also inhibit COX-2, which reduces inflammation, pain, and fever, so they have the same indications as aspirin.

However, ibuprofen, naproxen, and indomethacin are also used to reduce inflammation during an acute gout attack, where aspirin should be avoided since it competes with uric acid for excretion in the kidneys, which might worsen the symptoms of gout.

Indomethacin is also used to close patent ductus arteriosus in neonates and premature infants, while ketorolac is used to treat severe acute pain, usually after surgery.

Now moving on to selective COX-2 inhibitors, the main medication in this group is celecoxib.

Celecoxib reversibly inhibits COX-2, so it can treat pain and inflammation like the other NSAIDs.

Since it doesn’t affect COX-1, it lacks the antiplatelet effect seen in aspirin. On the other hand, it doesn’t compete with aspirin for COX-1 like the reversible nonselective COX inhibitors, so it can be combined with aspirin without decreasing its antiplatelet effect.

For side effects, both aspirin and the nonselective COX inhibitors can cause problems by blocking COX-1 in many parts of the body.

Inhibition of COX-1 in the stomach decreases the concentration of cytoprotective prostaglandins, which can lead to gastritis, gastric ulcers, or even bleeding.

Reversible inhibitors of COX-1 cause less gastrointestinal problems when compared to aspirin, and selective COX-2 inhibitors like celecoxib causes the least GI side effects since they don’t affect COX-1.

In the kidneys, all NSAIDs inhibit COX-2 which decreases the level of prostaglandins that dilate the renal artery, causing a reduction in renal blood flow. This reduced blood flow tricks the kidney into thinking the blood pressure is low, so in order to increase it, they activate the renin-angiotensin-aldosterone system, which can lead to hypertension.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Aspirin and NSAIDs; benefits and harms for the gut" Best Pract Res Clin Gastroenterol (2012)
  5. "Gastrointestinal safety of selective COX-2 inhibitors" Curr Pharm Des (2002)
  6. "Clinical pharmacology of selective COX-2 inhibitors" Int J Immunopathol Pharmacol (2003)
  7. "The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance?" Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy (2013)